跳到正文
原文
Medical Xpress·· 20 天前AI 评分56

PinkDx 阴道拭子检测在 16 家美国站点研究,或让部分女性免于子宫内膜癌活检

New swab test could spare some women a painful biopsy for endometrial cancer

AI 导读

PinkDx 正在美国 16 家站点研究一种阴道拭子检测,用于有绝经后出血等症状的女性判断是否患子宫内膜癌,目标是让部分人免去活检。此前在 27 名接受子宫切除术的女性中,该检测从阴道口拭子中检出了肿瘤基因信号;当前研究计划入组约 3000 人,预计今年完成,公司称早期结果符合预期,目标检出至少 90% 的癌症。

正文
swab test
Credit: Pixabay/CC0 Public Domain

A simple vaginal swab may one day help women with abnormal bleeding learn whether they have endometrial cancer without first going through a painful biopsy.

The test, from California-based PinkDx, is being studied at 16 U.S. sites, The Washington Post reported. It's meant for women who already have symptoms, such as bleeding after menopause.

Endometrial cancer starts in the lining of the uterus. Doctors often check for it with a transvaginal ultrasound, which uses a probe in the vagina to measure that lining. They may also do an endometrial biopsy, scraping out a small tissue sample through a thin tube passed into the uterus.

Both can be painful. Biopsies also fail to collect enough tissue about 30% of the time in women past menopause, The Post reported. Sometimes the uterine lining is too thin, or the cervix is too narrow for the instrument.

Meanwhile, endometrial cancer death rates are on the rise. That's partly because aggressive forms of the disease are becoming more common, The Post noted.

"Of all the cancers, this is one that is getting more and more cases being diagnosed every year," Dr. June Hou, a gynecologic oncologist at Columbia University Irving Medical Center in New York City, told The Post. She's leading the PinkDx study there.

Dying cancer cells in the uterus shed bits of genetic material that carry the tumor's fingerprint. These fragments can drift down into the vagina, where a swab taken by a clinician can collect them for lab testing.

In an early test of 27 women having a hysterectomy, PinkDx found that signal even in swabs from the vaginal opening.

Dr. Nicolas Wentzensen, deputy director of the Clinical Genetics Branch at the National Cancer Institute, told The Post that the first effort was very small. Its findings still need to be confirmed in a larger, independent group, he said.

The current study plans to enroll about 3,000 women and is expected to wrap up this year. Company officials told The Post that early results are on target.

The goal is for the swab to catch at least 90% of cancers. It also needs to correctly rule out cancer in at least half of women who don't have it, which limits false alarms.

If those numbers hold, Wentzensen said, the swab could become a first step that spares "half of the population from doing the biopsy."

Women who test positive would likely still need a biopsy. Those who test negative should still follow up with their doctor to evaluate other causes of their symptoms.

Because PinkDx plans to run the test only in its own lab, it doesn't need U.S. Food and Drug Administration approval, The Post reported.

The company expects to finish certification with the Centers for Medicare & Medicaid Services by early 2027. That would allow the swab to reach patients by mid-2027.

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

© 2026 HealthDay. All rights reserved.

Citation: New swab test could spare some women a painful biopsy for endometrial cancer (2026, October 30) retrieved 30 October 2026 from https://medicalxpress.com/news/2026-10-swab-women-painful-biopsy-endometrial.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com